Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

60.56
-0.2100-0.35%
Post-market: 60.560.00000.00%19:30 EDT
Volume:628.83K
Turnover:38.08M
Market Cap:5.85B
PE:-12.87
High:61.05
Open:60.77
Low:60.00
Close:60.77
52wk High:72.66
52wk Low:35.60
Shares:96.64M
Float Shares:95.45M
Volume Ratio:0.88
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7061
EPS(LYR):-4.3646
ROE:-43.62%
ROA:-28.02%
PB:4.71
PE(LYR):-13.88

Loading ...

Assessing Xenon Pharmaceuticals (XENE) Valuation After Strong Recent Share Price Momentum

Simply Wall St.
·
Apr 18

Xenon Pharmaceuticals to present at Bloom Burton healthcare investor conference

Reuters
·
Apr 15

Xenon expands 2025 inducement equity plan share reserve to 1,175,000 shares

Reuters
·
Apr 14

Xenon highlights Phase 3 X-TOLE2 azetukalner data in focal onset seizures at AAN 2026

Reuters
·
Apr 07

How Positive Phase 3 Azetukalner Results and Upsized Financing Could Reframe Xenon Pharmaceuticals (XENE) Investors

Simply Wall St.
·
Mar 30

Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush

Dow Jones
·
Mar 16

Xenon Pharmaceuticals Inc : Wedbush Cuts Target Price to $63 From $64

THOMSON REUTERS
·
Mar 16

Wedbush Trims Price Target on Xenon Pharmaceuticals to $63 From $64, Keeps Outperform Rating

MT Newswires Live
·
Mar 16

H.C. Wainwright Keeps Their Buy Rating on Xenon (XENE)

TIPRANKS
·
Mar 16

Xenon Pharmaceuticals Closes $747.5 Million Public Offering

MT Newswires Live
·
Mar 13

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

GlobeNewswire
·
Mar 13

Xenon Pharmaceuticals President and CEO Ian Mortimer Disposes of Common Shares

Reuters
·
Mar 12

BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Nike, Unifirst

Reuters
·
Mar 11

Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00

TIPRANKS
·
Mar 11

Xenon Pharmaceuticals prices upsized USD 650 million public offering at USD 57 per share

Reuters
·
Mar 11

Xenon Pharmaceuticals Inc - Common Shares Offered at $57.00 per Share; Pre-Funded Warrants at $56.9999

THOMSON REUTERS
·
Mar 11

Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy

TIPRANKS
·
Mar 10

Wells Fargo Sticks to Their Buy Rating for Xenon (XENE)

TIPRANKS
·
Mar 10

Wedbush Adjusts PT on Xenon Pharmaceuticals to $64 From $47, Maintains Outperform Rating

MT Newswires Live
·
Mar 10

Small U.S. Stocks Close Up; Xenon Pharmaceuticals Climbs Highest

Dow Jones
·
Mar 10